(All fields required)
Please enter a valid email.
Please enter your name.
What is : (So we know you are human.)
Please supply the correct answer.
Craig Erickson, MD, is a leading expert in Fragile X Syndrome (FXS) and the director of the Fragile X Research and Treatment Center. His primary research focus is investigating novel approaches to the treatment of FXS. He has consistently received funding support from various sources, including FRAXA Research Foundation, The John Merck Foundation, Novartis Pharmaceuticals, and Seaside Therapeutics. Dr. Erickson is particularly interested if a medication, acamprosate, an mGluR5 antagonist, can improve social interaction and communication in individuals with FXS.
Use of Acamprosate in Individuals with Fragile X:
Dr. Erickson has just begun to investigate if acamprosate use in individuals with FXS can improve social interaction and communication. Dr. Erickson began this research three years ago at Indiana University School and Medicine and has been continuing his efforts at Cincinnati Children's. Dr. Erickson recently received a large grant to support is investigation on acamprosate.
Acamprosate is a FDA approved medication to treat alcoholism in adults. Animal research has shown that this medication acts as an antagonist at the mGlur5 receptor, which possibly plays a role in the FXS mutation. At Indiana University, Dr. Erickson completed and published several studies investigating this medication.
5 to 17 Year Olds with Fragile X Syndrome Needed for a Research Study
Kowalski JL, Wink LK, Blankenship K, Habenicht CD, Erickson CA, Stigler KA, McDougle CJ. Paliperidone palmitate in a child with autistic disorder. J Child Adolesc Psychopharmacology. Oct;21(5):491-3. 2012
Wink LK, Erickson CA, Stigler KA, McDougle CJ. Riluzole in autistic disorder. Journal of Child and Adolescent Psychopharmacology. Aug;21(4):375-9. 2012.
Erickson CA, Early M, Wink LK, McDougle CJ. An open-label naturalistic pilot study of acamprosate in youth with autistic disorder. Journal of Child Adolescent Psychopharmacology. Dec;21(6):565-9. 2012.
Erickson CA, Stigler KA, Wink LK, Mullett JE, Kohn A, Posey DJ, McDougle CJ. A prospective open-label study of aripiprazole in fragile X syndrome. Psychopharmacology. Jul;216(1):85-90. 2011.
Erickson CA, Stigler KA, Wink LK, Weng N, Weiler IJ, Greenough WT, McDougle CJ. Open-label riluzole in fragile X syndrome. Brain Research, 1380: 264-70. 2011.
Wink LK, Erickson CA, Chambers JE, McDougle CJ. Comorbid intellectual disability and borderline personality disorder: A case series. Psychiatry. 73(3): 279-289. 2010.
Stigler KA, Erickson CA, Mullett JE, Posey DJ, McDougle CJ. Paliperidone for irritability in autistic disorder. J Child Adolesc Psychopharmacol. Feb;20(1):75-8, 2010.
Wink LK, Erickson CA, McDougle CJ. Pharmacologic treatment of behavioral symptoms associated with autism and other pervasive developmental disorders. Current Treat Options Neurology. 12: 529-538, 2010.
Erickson CA, Mullett JE, McDougle CJ. Brief Report: Acamprosate in fragile X syndrome. J Autism Dev Disorder. Nov;40(11):1412-6. 2010.
The Cincinnati Children’s Hospital Research Foundation
The John Merck Fund
FRAXA Research Foundation
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY: 1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2015 Cincinnati Children's Hospital Medical Center